Company: INTS
Filing Date: 2025-06-12
Form Type: 424B5
Source: 0001628280-25-031040
Chunk: 13

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-12
Form: 424B5
Chunk 13
---
 under this prospectus supplement. See “Use of Proceeds.” |
| Risk Factors                                       |     | Investing in our securities involves significant risks. Please read the information contained in or incorporated by reference under the heading “Risk Factors” beginning on pageS-9of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

The number of shares of common stock shown above to be outstanding after this offering is based on 18,398,202 shares outstanding as of June 11, 2025 and excludes: • 4,040,801 shares of common stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $4.10 per share; • 8,308,229 shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock with a weighted average exercise price of $1.70 per share; and • 957,277 additional shares of the Common Stock reserved for future issuance under our equity incentive plans. Unless otherwise indicated, the discussion and table above assumes (i) no exercise of the outstanding options and warrants described above and (ii) no exercise by the representative of the underwriters of its option to purchase additional shares of common stock from us.

<div align='center'>S-8</div>

### RISK FACTORS
Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described below and in our most recent Annual Report on Form 10-K for the year ended December 31, 2024, as updated or superseded by the risks and uncertainties described in our subsequent filings under the Exchange Act, each of which is incorporated by reference into this prospectus supplement and the accompanying prospectus, and all of the other information in this prospectus supplement and the accompanying prospectus, including our financial statements and related notes incorporated by reference in this prospectus supplement and the accompanying prospectus. If any of these risks is realized, our business, financial condition, results of operations and prospects could be harmed. In that event, the trading price of our common stock could decline and you could lose part or all of your investment. Additional risks and uncertainties that are not yet identified or that we think are immaterial may also harm our business, operating results and financial condition and could result in a complete loss of your investment.

Risks Related to this Offering and Our Common Stock